Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Lung Cancer
DRUG: Amrubicin hydrocloride|DRUG: Docetaxel
Progression free survival, 3.3 months
Overall survival, 12 months|response rate (RECIST), 3 months|Number of Participants with Adverse Events, 4 months
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).